For Immediate Release

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and CEO
(Code no.: 4568, First Section, Tokyo Stock Exchange)
Please address inquiries to Junichi Onuma,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
https://www.daiichisankyo.com

Daiichi Sankyo Announces Changes to Representative Directors and Members of the Board

Tokyo, Japan, (May 11, 2020) – Daiichi Sankyo Company, Limited (hereinafter, the Company) today announced that its Board of Directors approved changes to its Representative Directors and Members of the Board as follows.

 

1.  Retirement of Representative Director (as of June15, 2020)

　Reason for change:

Ten years after George Nakayama assumed the position of Representative Director, the Company has advanced the transformation toward realizing its 2025 Vision of becoming a “Global Pharma Innovator with competitive advantage in oncology” set forth in 5-year Business Plan. The change announced today will enable a new management team to further promote our growth strategy in the future.

 

Retiring Representative Director

 

2.  Changes to Members of the Board (as of June 15, 2020)

　Appointments will be subject to approval at the Company’s 15th Annual General Meeting of Shareholders on June 15, 2020.

 

(1) New candidates for Member of the Board

●Masahiko Ohtsuki

             (Senior Executive Officer, Head of Digital Transformation Management Division)

●Shoji Hirashima              

             (Senior Executive Officer, Head of Global Brand Strategy Division)

 

(2) Retiring Members of the Board

●George Nakayama            (Representative Director, Chairman)

●Toshiaki Tojo       (Member of the Board)

* George Nakayama and Toshiaki Tojo will be appointed a Senior Adviser and Corporate Adviser at the Company, respectively.

  

Attachment

 

Curriculum Vitae: Candidates for Member of the Board

 

Masahiko Ohtsuki: Born October 13, 1959

Current Position Held: Senior Executive Officer, Head of Digital Transformation Management Division, Daiichi Sankyo Company, Limited

Career Summary

Apr.  1987      Entered Sankyo Co., Ltd.

Apr.  2010      Vice President, R&D Planning Department, R&D Division of the Company

Apr.  2012      Vice President, Research Oversight Function, R&D Division of the Company

Apr.  2013      Vice President, Research Oversight Function, R&D Division of the Company

Apr.  2014      Corporate Officer, Vice President of Research Oversight Function, R&D Division of the Company

Apr.  2018      Corporate Officer, Vice President of Business Development & Licensing Department of the Company

Apr.  2019      Executive Officer, Vice President of Business Development & Licensing Department of the Company

Apr.  2020      Senior Executive Officer, Head of Digital Transformation Management Division of the Company (to present)

 

Shoji Hirashima: Born March 6, 1961

Current Position Held: Senior Executive Officer, Head of Global Brand Strategy Division, Daiichi Sankyo Company, Limited

Apr.  1988      Entered Daiichi Pharmaceutical Co., Ltd.

Apr.  2010      CEO of U3 Pharma GmbH

Apr.  2015      Vice President, Corporate Strategy Department, Corporate Strategy Division of the Company

Apr.  2016      Vice President of Corporate Strategy Department and Senior Director of Oncology Business Group, Corporate Strategy Division of the Company

Apr.  2017      Corporate Officer, Vice President of Corporate Business Management Department, Corporate Strategy and Management Division of the Company

Apr.  2019      Executive Officer, Head of Global Brand Strategy Division of the Company

Apr.  2020      Senior Executive Officer, Head of Global Brand Strategy Division of the Company (to present)

 

For Reference:

Members of the Board, Members of the Audit and Supervisory Board after the election at the Ordinary General Meeting of Shareholders (as of June 15, 2020)

Name	Positions and Assignments
Sunao Manabe	Representative Director, Member of the Board, President and CEO
Toshiaki Sai	Representative Director, Member of the Board, Executive Vice President and CFO, Head of Corporate Strategy & Management Division
Satoru Kimura	Member of the Board, Senior Executive Officer, Head of Sales & Marketing Division
Masahiko Ohtsuki	Member of the Board, Senior Executive Officer, Head of Digital Transformation  Management Division
Shoji Hirashima	Member of the Board, Senior Executive Officer, Head of Global Brand Strategy Division
Noritaka Uji	Member of the Board (Outside)
Tsuguya Fukui	Member of the Board (Outside)
Kazuaki Kama	Member of the Board (Outside)
Sawako Nohara	Member of the Board (Outside)
Ryoichi Watanabe	Member of the Audit and Supervisory Board
Kenji Sato	Member of the Audit and Supervisory Board
Sayoko Izumoto	Member of the Audit and Supervisory Board (Outside)
Tateshi Higuchi	Member of the Audit and Supervisory Board (Outside)
Yukiko Imazu	Member of the Audit and Supervisory Board (Outside)

 

About Daiichi Sankyo
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders. For more information, please visit: www.daiichisankyo.com/